drugset

drugset / Trial / NCT07348055

A Study of GR1803 in Systemic Lupus Erythematosus

NCT07348055 ↗

Phase 1/2 Recruiting 44 enrolled Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Non-randomizedSequentialOpen-labelTreatment

Summary

to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus

Timeline

Start: 2026-02-02
Primary completion: 2027-06-01
Completion: 2027-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GR1803	Unknown	—	—

Indications